title: Tibolone in the treatment of psychosomatic symptoms in menopause.
abstract: The purpose of this study was to investigate the value of tibolone in the treatment of psychosomatic symptoms in menopause. Forty-two menopausal women (aged 46-63, mean 53.9) with nightly perspiration, vasomotor flushes, disturbance of libido, dyspnea and other psychosomatic symptoms were assigned to one of two treatment groups for three months: 1st group) 21 users of tibolone; 2nd group) 21 users of placebo. At the end of the trial disturbance of libido was observed in 4 (19.0%) cases tin the 1st group and 11 (52.4%) cases in the 2nd (p < 0.05) and nightly perspiration was observed in 3 cases (14.3%) in the 1st group and 9 cases (42.9%) in the 2nd (p < 0.05). Although vasomotor flushes were observed in only 3 (14.3%) cases in the 1st group and 7 cases (33.3%) in the 2nd group, this difference was not significant (p > 0.05). There was no significant effect of tibolone or placebo in dyspnea, vertigo and headache. From the results it can be concluded that tibolone can have a beneficial effect on some psychosomatic symptoms in postmenopausal women.
authors.affiliation: Department of Obstetrics & Gynecology, Elena Venizelou Hospital, Athens, Greece.
authors.forename: E M
authors.initials: EM
authors.lastname: Argyroudis
authors.forename: G
authors.initials: G
authors.lastname: Iatrakis
authors.forename: A
authors.initials: A
authors.lastname: Kourkoubas
authors.forename: N
authors.initials: N
authors.lastname: Georgoulias
authors.forename: G
authors.initials: G
authors.lastname: Kourounis
authors.forename: C
authors.initials: C
authors.lastname: Tsionis
authors.forename: Z
authors.initials: Z
authors.lastname: Prapa
authors.forename: K
authors.initials: K
authors.lastname: Karamanos
authors.forename: I
authors.initials: I
authors.lastname: Diakakis
authors.forename: L
authors.initials: L
authors.lastname: Giannikos
authors.forename: J
authors.initials: J
authors.lastname: Ladopoulos
mesh_terms: D045930:Anabolic Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008593:Menopause / Q000523:psychology*; D008875:Middle Aged; D009652:Norpregnenes / Q000627:therapeutic use*; D011602:Psychophysiologic Disorders / Q000188:drug therapy*
chemical_list: D045930:Anabolic Agents; D009652:Norpregnenes; C027385:tibolone